TY  - JOUR
AU  - Drwesh, Layla
AU  - Arena, Giuseppe
AU  - Merk, Daniel J
AU  - Ferrante, Daniele
AU  - Gorgogietas, Vyron
AU  - Gasser, Thomas
AU  - Grünewald, Anne
AU  - May, Patrick
AU  - Brockmann, Kathrin
AU  - Krüger, Rejko
AU  - Wüst, Richard
AU  - Gloeckner, Christian Johannes
AU  - Fitzgerald, Julia C
TI  - Methodological validation of Miro1 retention as a candidate Parkinson's disease biomarker.
JO  - npj Parkinson's Disease
VL  - 11
IS  - 1
SN  - 2373-8057
CY  - [London]
PB  - Springer Nature
M1  - DZNE-2025-01103
SP  - 270
PY  - 2025
AB  - Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.
LB  - PUB:(DE-HGF)16
C6  - pmid:40954161
C2  - pmc:PMC12436598
DO  - DOI:10.1038/s41531-025-01115-8
UR  - https://pub.dzne.de/record/281356
ER  -